Skip to content

Reproducibility of overall survival in metastatic colorectal cancer randomized trials using ARCAD-Derived external control arms.

Aug 2026 · Journal of the National Cancer Institute · 0 citations
Medicine

TL;DR

ARCAD-derived SCAs reliably reproduced control-arm OS and benchmark treatment-effect estimates from landmark RCTs in mCRC, and supports benchmarking, trial design, and exploratory analyses when conventional control arms are impractical.

View source

Similar papers

Review Aug 2026

Recurrence-Free Survival Dynamics Following Adjuvant Chemotherapy for Resected Cancers of the Gastrointestinal Tract: A Systematic Review of Randomized Controlled Trials.

Improvements in RFS associated with active adjuvant chemotherapy regimens are driven by early changes in recurrence dynamics, which may provide in vivo understanding of residual tumor cell populations after curative-intent resection and how chemotherapy can be best used to prevent recurrence.

Jennie Choe, Sreya Sanyal, Ying-Ting Zhang et al. · 0 citations
Review Open access Aug 2026

Comparative efficacy of therapeutic strategies for recurrent or refractory glioblastoma: a systematic review and network meta-analysis

Background Recurrent or refractory glioblastoma has a poor prognosis, and no universally accepted standard treatment has been established. Randomized evidence is fragmented, making pairwise comparisons insufficient. This study aimed to compare available treatments using a frequentist network meta-analysis. Methods PubM...

Hao Zhang, Lei-Lei Sun, Zhi-He Yun et al. · 0 citations
Meta-analysis Open access Sep 2026

Overall survival in oncology phase III trials: an individual patient level meta-analysis (OPTIMA)

Abstract Designing phase III oncology trials to demonstrate overall survival (OS) superiority may be challenging due to sample size, follow-up time, resources, and costs as compared to trials evaluating intermediate endpoints, which may or may not be reliable surrogates of OS. In this study, we investigate at scale the...

A. Sherry, N. Meimoun, A. Miller et al. · 0 citations
Review Open access Sep 2026

Immune checkpoint inhibitors across neoadjuvant, perioperative, and adjuvant settings for resectable non-small-cell lung cancer: a systematic review and meta-analysis of randomized trials

Background Randomized evidence for immune checkpoint inhibition in resectable non-small-cell lung cancer has progressed from pathological response to mature survival outcomes. We examined exploratory directional alignment across endpoints and quantified clinical yield, treatment burden, and the extent of perioperative...

J. Dai, Meng-Ni Liu, Hu Li et al. · 0 citations
Open access Sep 2026

Constructing an External Control Arm Using the French REALYSA Cohort to Replicate Outcomes of a Randomized Trial Arm in Advanced Hodgkin Lymphoma

External control (EC) arms using routine data can be used as comparators in clinical trials under certain conditions. The objective of this study was to assess the ability of an EC arm to replicate outcomes of a randomized controlled trial (RCT) arm receiving the same treatment strategy in advanced stage classical Hodg...

O. Febvey-Combes, Cédric Rossi, B. Kassai et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.